Background: HCV treatment showed dramatical change due to the introduction of potent,
strong, direct antiviral drugs. Before the appearance of Direct-acting antivirals, multiple
therapeutic interventions were used for hepatitis C, but none of these interventions were effective
on patient-centered outcomes. Direct-acting antivirals cause disruption of viral replication because
they target specific nonstructural viral proteins.
Aim: To review the advantages of efficient HCV therapy and its long term drawbacks.
Methods: A search of the literature published in indexed databases (PubMed, Medline In-Process,
and Embase) within the last 5 years was conducted. Any duplicated citations were excluded before
first-pass screening. Citations (titles and abstracts) were screened for eligibility by a single
reviewer. Full texts (including congress abstracts, posters and other congress communications) of
citations deemed relevant during title and abstract screening were retrieved for second-pass review.
Results: Studies on the clinical effects of DAAs for hepatitis C show better tolerance, improved
survival and fewer complications when compared to previous interferon therapy.
Conclusion: HCV treatment has improved dramatically. Since that time, there are multiple approved
oral therapies all with high efficacy. The most important factor which should be considered
during choosing appropriate therapy is to ensure that it covers the viral genotype of the infected